Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis

Reuters

2025/10/01

<a href="https://laohu8.com/S/EVFM">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis

**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates $(UAE)$ Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis $(BV)$ and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572531937"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572531937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572531937?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572531937","market":"nz","top_or_hot":-1,"title":"Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis <a href=\"https://laohu8.com/S/BV\">$(BV)$</a> and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-01 20:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a>' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates <a href=\"https://laohu8.com/S/UAE\">$(UAE)$</a> Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis <a href=\"https://laohu8.com/S/BV\">$(BV)$</a> and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL88mtnb:1","article_id":"2572531937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572531937","pubTimestamp":1759322849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates  Ministry of Health and Prevention for SOLOSEC  2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis  and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EVFM":"Evofem Biosciences, Inc.","BK4584":"避孕概念"},"translate_title":"Evofem Biosciences的SOLOSEC®阿联酋正在接受治疗细菌性阴道病和滴虫病的监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences' SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis\n    \n\n        **Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC® in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates $(UAE)$ Ministry of Health and Prevention for SOLOSEC® (secnidazole) 2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC®, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis $(BV)$ and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA87990) on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}